Related Experiment Video

Updated: Apr 16, 2026

Isolation and Culture of Adult Epithelial Stem Cells from Human Skin
08:26

Isolation and Culture of Adult Epithelial Stem Cells from Human Skin

Published on: March 31, 2011

29.2K

Innovative therapeutic strategies for recessive dystrophic epidermolysis bullosa

F Larcher1, M Del Río2

  • 1División de Biomedicina Epitelial, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, España; Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Madrid, España; Instituto de Investigaciones Sanitarias de la Fundación Jimenez Díaz (IIS-FJD), Madrid, España.

Actas Dermo-Sifiliograficas
|March 23, 2015
PubMed

Insights

Recessive dystrophic epidermolysis bullosa (RDEB) is a severe rare skin disease caused by collagen VII deficiency. Advanced therapies aim to restore collagen VII, potentially improving skin integrity and quality of life for RDEB patients.

Area of Science:

  • Dermatology
  • Genetics
  • Regenerative Medicine

Background:

  • Recessive dystrophic epidermolysis bullosa (RDEB) is a severe inherited skin blistering disorder.
  • It results from mutations in the COL7A1 gene, leading to collagen VII deficiency.
  • Current treatment focuses on wound care and symptom management.

Purpose of the Study:

  • To review the advanced therapeutic interventions under development for RDEB.
  • To highlight the potential of these therapies in restoring dermal-epidermal adhesion.
  • To discuss the impact on patient quality of life.

Main Methods:

  • Review of current research and clinical trials for RDEB therapies.
  • Analysis of therapeutic strategies including protein, cell-based, and gene-based approaches.
  • Evaluation of potential efficacy and scope of treatment.

Main Results:

  • Multiple advanced therapeutic strategies are in development for RDEB.
  • These therapies aim to replenish collagen VII to improve skin structure.
  • Some approaches may also address internal mucosal involvement.

Conclusions:

  • Novel therapies show promise for treating RDEB.
  • Restoring collagen VII is a key therapeutic goal.
  • Significant improvements in patient quality of life are anticipated in the near future.
Keywords:
Advanced therapiesEpidermolysis bullosaEpidermólisis bullosaGeneticsGenodermatosisGenéticaTerapias avanzadas

More Related Videos

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

7.3K
CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors07:44

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

8.9K

Related Concept Videos

Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.4K
Renewal of Skin Epidermal Stem Cells01:12

Renewal of Skin Epidermal Stem Cells

The skin is divided into epidermis, dermis, and hypodermis, the skin's outermost, middle, and inner layers. The human epidermal layer regularly undergoes renewal, where old, dead cells are replaced by new cells. Epidermal stem cells or EpiSCs divide and differentiate to restore the lost cells. For the renewal process, some EpiSCs continuously self-renew. In contrast, few others differentiate into transit-amplifying cells, which later form prickle or spinous cells, followed by granular...
3.3K